Nestlé Ghana has launch a comprehensive cancer care program for its employees and their dependants in partnership ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Gavreto used to treat metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer.

Today marks the opening of Postmedia’s popular Support and Buy Local Auction, providing savvy British Columbians with the ...

Cal Moody is the latest from his family to take the snaps for the Warriors, who face Winthrop in a matchup of unbeaten Class ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering AAV capsids.

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Roche has inked a new deal with Dyno Therapeutics to develop next-generation AAV capsids for gene therapies targeting ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.The ...